Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome.
about
Relation between dietary n-3 and n-6 fatty acids and clinically diagnosed dry eye syndrome in womenTopical ciclosporin in the treatment of ocular surface disordersDry eye: an inflammatory ocular diseaseThe pathophysiology, diagnosis, and treatment of dry eye diseaseTreatment of primary Sjögren syndrome.Managing Sjögren's Syndrome and non-Sjögren Syndrome dry eye with anti-inflammatory therapy.Dry eye disease.Medically reversible limbal stem cell disease: clinical features and management strategiesThe core mechanism of dry eye disease is inflammation.Fluorescein punctate staining traced to superficial corneal epithelial cells by impression cytology and confocal microscopyMatrix metalloproteinase-9 knockout confers resistance to corneal epithelial barrier disruption in experimental dry eyeA review on recent advances in dry eye: Pathogenesis and managementLong-Term Outcome of Treatment with Topical Corticosteroids for Severe Dry Eye Associated with Sjögren's Syndrome.Tear dysfunction and the cornea: LXVIII Edward Jackson Memorial Lecture.Cyclosporine immunomodulation retards regeneration of surgically transected corneal nerves.Topical 0.05% cyclosporin in the treatment of dry eye.Ocular surface immunity: homeostatic mechanisms and their disruption in dry eye diseaseCorrelation between optical coherence tomography-derived assessments of lower tear meniscus parameters and clinical features of dry eye disease.Topical fluorometholone treatment for ocular dryness in patients with Sjögren syndrome: a randomized clinical trial in ChinaEfficacy of topical blockade of interleukin-1 in experimental dry eye diseaseImprovement of Outcome Measures of Dry Eye by a Novel Integrin Antagonist in the Murine Desiccating Stress Model.Topical steroid and non-steroidal anti-inflammatory drugs inhibit inflammatory cytokine expression on the ocular surface in the botulinum toxin B-induced murine dry eye model.Survey of eye practitioners' attitudes towards diagnostic tests and therapies for dry eye disease.Improvement in the signs and symptoms of dry eye disease with dobesilate eye dropsPERSIST: Physician's Evaluation of Restasis(®) Satisfaction in Second Trial of topical cyclosporine ophthalmic emulsion 0.05% for dry eye: a retrospective review.Comparison of the Anti-Inflammatory Effects of Artificial Tears in a Rat Model of Corneal Scraping.National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report.The Effect of Autologous Platelet Lysate Eye Drops: An In Vivo Confocal Microscopy StudyA randomized, double-blind, placebo-controlled study of oral antioxidant supplement therapy in patients with dry eye syndrome.Dry eye disease: an immune-mediated ocular surface disorder.A Clinical Trial Comparing the Safety and Efficacy of Topical Tacrolimus versus Methylprednisolone in Ocular Graft-versus-Host DiseaseOcular manifestations of graft-versus-host diseaseInterleukin-1β and tumour necrosis factor-α levels in conjunctiva of diabetic patients with symptomatic moderate dry eye: case-control study.Treatment of chronic dry eye: focus on cyclosporineThe role of inflammation and antiinflammation therapies in keratoconjunctivitis sicca.Inflammatory cytokine and osmolarity changes in the tears of dry eye patients treated with topical 1% methylprednisolone.sPLA2-IIa is an inflammatory mediator when the ocular surface is compromisedPharmacotherapy of dry eye.Primary Sjögren syndrome: an update on current pharmacotherapy options and future directions.Towards a dynamic customised therapy for ocular surface dysfunctions.
P2860
Q24537414-1BAC8040-2679-4668-8860-B00D065760AAQ24670344-2A9B55E2-CA7F-4C77-B511-9FB812D4CBC0Q26852044-7DE7E18E-E653-47DB-A354-84E85C3A3D53Q28083825-6233080E-9F4F-41DF-9546-E12FEB57E808Q30249011-95909ACA-CD0B-4C94-81D1-3D36AAD33B1FQ34028408-F9B79BB8-1146-40AE-B7C4-E6074C991D4CQ34123349-15076529-34AB-4075-9708-265055A44293Q34257547-C1E63803-886F-4C87-9BF8-387377CF159BQ34510429-BBF0F31E-CE9B-4962-BB65-F0D8B27878ECQ34824116-A8AD709C-7C19-4D6E-84E7-C99675436E0BQ35083557-5AF04FE2-1281-4069-AAD4-9E363C0187B2Q35176597-E0B3D4F8-61F8-440B-8445-3DB4B5C7E50CQ35529254-0B8F4813-9886-473A-8866-5BE26E71364CQ35570793-FF9AD784-2A8A-4F58-898C-77070E294386Q35865430-42251981-0C94-448F-AF3F-0825893D171EQ35906913-1791BE00-2E75-4ACF-ABCF-E248F80BA5BBQ35907009-BE7F1CC7-F282-4A7A-99F4-4AC6188DA89AQ35957497-8F334C76-1082-4BA8-A7C4-1493F7A2014CQ36009560-FAD7EF56-76EE-4BB2-87A5-20093B83A035Q36044544-783F4C4F-7BAE-4D2C-9E4D-D02177FB972FQ36050556-69B15762-F439-484D-B559-5D0CC844C295Q36099684-A8138371-98D1-4CD2-A823-55044A4266BFQ36201636-0F049BDA-5E07-4DE3-B89C-8D5D4197AD5BQ36393194-9ED707A5-A9E4-451D-B5D4-D7A1170386A5Q36444344-D00FB53B-E319-4190-9048-9EBB171046E4Q36656777-62E10976-CD7E-4346-B628-1B43FA6BFCE9Q36766324-A0DCFCD1-9441-4C11-8141-115CE5008C04Q36864045-841F599A-916F-4469-BA4C-CE6ED4C70209Q36908429-B7F14CE2-EE6F-4B80-AEEB-3E791D11E95BQ36916372-FADC0C62-DF4B-4EF6-980E-0EA2D0BE92B5Q37038747-B22DB6B0-905C-4F46-9008-3419D187D4ADQ37163474-E3C80C20-5030-4553-ABE6-4FEC9B645B78Q37177382-DDE0A624-7E4F-45FC-826F-8D4E3B153730Q37236096-8973F365-DFC6-49C8-AB55-9412828CE67EQ37257746-97C150D4-003D-497A-B835-82AD50883B3DQ37418879-C786BFAB-184B-4717-92F4-5E4B7E455647Q37726033-FA3A39F0-2439-4238-A032-7C4705F0BB65Q37826752-E76A52F8-6CB0-46B6-BC0E-0A81E7E6B375Q38076460-E746EDE4-AD16-4818-8D34-B51FCE7D0E38Q38098900-C9002705-994D-4832-8D22-16A889C7002A
P2860
Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome.
description
1999 nî lūn-bûn
@nan
1999 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Topical nonpreserved methylpre ...... tis sicca in Sjögren syndrome.
@ast
Topical nonpreserved methylpre ...... tis sicca in Sjögren syndrome.
@en
type
label
Topical nonpreserved methylpre ...... tis sicca in Sjögren syndrome.
@ast
Topical nonpreserved methylpre ...... tis sicca in Sjögren syndrome.
@en
prefLabel
Topical nonpreserved methylpre ...... tis sicca in Sjögren syndrome.
@ast
Topical nonpreserved methylpre ...... tis sicca in Sjögren syndrome.
@en
P1433
P1476
Topical nonpreserved methylpre ...... tis sicca in Sjögren syndrome.
@en
P2093
Pflugfelder SC
P304
P356
10.1016/S0161-6420(99)90171-9
P577
1999-04-01T00:00:00Z